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Introduction
Prostate cancer is the most common cancer in men in the United
Kingdom (UK), with over 42,000 men being diagnosed with the
condition every year [1]. It is the second most common cancer in men
worldwide. More than 1.1 million cases of prostate cancer were
diagnosed in 2012 [2]. The use of Prostate-Specific Antigen (PSA)
testing has led to an overall increase in the incidence of prostate cancer
rates [3]. Its use has also resulted in the early detection of a large
number of localised prostate cancer cases, which do not pose a threat
to patients’ health or lives [4]. Prostate cancer detected by PSA
screening tend to be detected at an earlier stage and take longer to
progress without any treatment compared to cancers detected because
of clinical manifestations. Autopsy studies have shown a high
prevalence of asymptomatic localised prostate cancer in men who have
died of other causes [5]. The management of localised prostate cancer
therefore remains a controversial issue. A significant number of
patients are undergoing treatment for clinically insignificant disease,
with subsequent decrease in their quality of life due to treatment-
related side-effects [6]. Active surveillance (AS) is a reasonable strategy
to avoid overtreatment of low-risk localised prostate cancer and has
now become a standard approach. Data from the British Association of
Urological Surgeons (BAUS) have shown that up to 40% of men with
low-risk disease have opted for active surveillance [7].
Defining Low-Risk Prostate Cancer
The basic idea behind active surveillance is that some prostate
cancers will not progress to the stage that requires treatment within the
lifetime of the patient and therefore treatment can be avoided or
delayed [8]. This management strategy relies on careful risk
stratification in order to identify patients with cancers at low risk of
progression. Categorising patients into the low-risk group remains
very challenging. Various clinical parameters such as Gleason score,
clinical stage and pre-treatment PSA are used to stratify patients in the
different groups and estimate the long-term disease progression.
The Epstein criteria, first described in 1994, are commonly used to
describe disease risk [9]. They were developed for men who underwent
radical prostatectomy for what was considered insignificant disease:
tumour size <0.5 cm3, organ-confined disease, and no Gleason pattern
4 or 5. The pre-operative predictors associated with these tumours
include no Gleason pattern 4 or 5 in the biopsy specimen and either a
PSA density of ≤ 0.1 ng/ml per gram, less than three positive biopsy
cores out of a minimum of six cores, and no cores with >50%
involvement; or a PSA density of ≤ 0.15 ng/ml per gram and cancer
smaller than 3 mm on only one biopsy core [6]. The Epstein criteria are
still widely used to define clinically insignificant prostate cancer.
D’Amico et al. described another risk classification for patients with
prostate cancer using clinical stage, pre-treatment PSA and Gleason
score to place patients in low, intermediate, or high risk of PSA
recurrence after radical prostatectomy or radiotherapy [10]. The
D’Amico criteria have been shown to predict disease-specific mortality
in men undergoing radical prostatectomy [11]. Although both the
Epstein and D’Amico criteria were developed to predict the outcomes
in men treated for prostate cancer, they are commonly used to identify
patients suitable for active surveillance (Table 1).
Study Clinical Stage Gleason Score PSA
Epstein et al. [9] ≤ T1c No Gleason pattern 4 or 5 PSA density of ≤ 0.15 ng/mL/g
<3 positive cores (out of 6)
<50% single core involvement
D’Amico et al. [10] ≤ T2a No Gleason pattern 4 or 5 PSA level ≤ 10 ng/mL
NICE [12] T1-T2a Gleason ≤ 6 PSA level <10 ng/mL
EAU [13] T1-T2a Gleason<7 PSA level <10 ng/mL
EAU = European Association of Urology; NICE = National Institute for Health and Care Excellence
Table 1: Some of the different criteria used to define low-risk prostate cancer.
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Active Surveillance
With the widespread use of PSA testing and new protocols for
prostate biopsy, the incidence of low-risk prostate cancer has increased
[4]. There is an ongoing debate among clinicians whether to treat
prostate cancer early to prevent metastatic disease or to observe and
only offer treatment when there is evidence of disease progression. The
former is associated with risks of over-treating indolent disease
whereas the latter risks missing an opportunity for cure among
patients who will progress. Active surveillance (AS) has therefore
become a reasonable alternative for patients with clinically
insignificant disease. AS refers to a systematic programme where men
diagnosed with low-risk prostate cancer are periodically monitored
with multiple parameters including PSA, digital rectal examination
and repeat prostate biopsies. The aim of such an approach is to identify
disease progression in a timely fashion so that curative treatment can
be offered promptly with good outcomes. AS may spare patients with
early disease the side-effects of radical treatment without
compromising their survival. It is a credible solution to the problem of
overtreatment of clinically insignificant disease [14].
It is important to distinguish the concept of active surveillance from
watchful waiting. Watchful waiting involves lax observation of the
selected group of patients with late palliative treatment offered in the
event of disease progression. This approach is generally reserved for
elderly co-morbid patients. Active surveillance on the other hand
involves closer monitoring with early radical treatment offered in those
with signs of progression [15].
Patient Selection for Active Surveillance
The most important aspect of a successful active surveillance
programme is patient selection. Selection depends on patient and
tumour characteristics as well as patient’s preferences. Age, co-
morbidities and life expectancy are also important factors to consider.
Prospective studies with adequate follow-up and intervention data are
currently lacking when it comes to selecting the ideal patients. There
are currently no randomised controlled trials comparing the different
selection criteria. The Gleason score, clinical stage and PSA at
diagnosis are some of the criteria used for risk stratification. Both the
Epstein and D’Amico criteria for defining disease risk are commonly
used for selecting candidates for active surveillance. The inclusion
criteria used in the various studies are quite different as outlined in
Table 2 below.
Study Criteria for Inclusion in Active Surveillance
Dall’Era et al. [16] PSA ≤ 10 ng/mL, Gleason score ≤ 6, <33% positive cores, ≤ 50% single core involvement
PRIAS [17] T1c-T2, PSA ≤ 10 ng/mL, Gleason score ≤ 6, ≤ 2 positive cores, PSA density ≤ 0.2ng/g
Soloway et al. [18] T1a-T2, PSA ≤ 10 ng/mL, Gleason score ≤ 6, ≤ 2 positive cores, ≤ 20% single core involvement
Klotz et al. [19] No mention of stage, PSA ≤ 10 ng/mL, Gleason score ≤6, <3 positive cores, <50% single core involvement
NICE [20] T1-T2a, PSA<10 ng/mL, Gleason score ≤ 6, Consider AS for <T2b and PSA<20 ng/mL and Gleason 7 if active treatment not wanted
PRIAS = Prostate Cancer Research International: Active Surveillance
Table 2: Criteria for Inclusion in Active Surveillance
Active surveillance is offered to men who could have also been
offered radical treatment in the form of surgery or radiotherapy. It can
also be a suitable alternative for patients with intermediate-risk disease
and a life expectancy of less than 10 years. It is however not
recommended for patients with high-risk disease or those with
primary Gleason pattern 4 or 5 as they have a higher risk of
harbouring significant disease at diagnosis and progressing to
metastatic disease without treatment [21].
Active Surveillance Protocol
The surveillance schedule for patients on active surveillance varies
from centre to centre and there is currently no consensus on the
optimal strategy [22]. When counselling patients for AS, they should
be informed of the importance of compliance with the strict follow-up
schedule. Some of the criteria used as part of the follow-up include
digital rectal examination, PSA level, PSA kinetics and prostate re-
biopsy.
There is no consensus on whether repeat biopsies are necessary or
when they should be carried out. The NICE guidelines in the UK
recommend repeat prostate biopsies 12 months after enrolment on the
AS programme [23]. This is to rule out higher grade or volume disease
that may have been missed on the initial biopsy. The choice between
active treatment and continued surveillance is based on disease
progression at repeat biopsy [15]. The upgrading in Gleason score
remains the most important predictor of disease progression.
PSA remains a valid marker for the monitoring of patients on active
surveillance. According to D’Amico, a rapid rise in pre-treatment PSA
is associated with an increased risk of dying from prostate cancer [24].
Another study showed that a PSA doubling time of <2 years in patients
undergoing surgical treatment after a period of active surveillance was
a strong predictor of biochemical relapse [25]. Patients with PSA
doubling-time of less than 3 years were also found to have higher mean
PSA levels and more aggressive disease at re-biopsy [26]. However,
PSA kinetics should not be used to replace repeat biopsy for men on
AS [27].
Digital rectal examination as an independent predictor of disease
progression remains questionable. It might be difficult to detect subtle
changes on examination at such an early stage as it can be quite
subjective. A change in digital rectal examination is often unusual in
patients with low-risk disease [28]. One study showed that patients
with disease progression detected by DRE were more likely to have a
PSA doubling time of <2 years [29]. PSA kinetics therefore remains an
important tool for detecting progression (Table 3).
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Study PSA DRE Re-biopsy
Dall’Era et al. [16] Every 3 to 6 months Every 3 to 6 months At 12-24 months
PRIAS [17] First 2 years: every 3 months No mention At 1, 4 and 7 years
Next 2 years: every 6 months
Soloway et al. [18] First 2 years: every 3-4 months First 2 years: every 3-4 months Every 12 months
Next 2 years: every 6 months Next 2 years: every 6 months
Klotz et al. [19] First 2 years: every 3 months First 2 years: every 6 months At 6-12 months
Next 2 years: every 6 months Next 2 years: every 12 months
NICE [20] First year: every 3-4 months First 5 years: every 6-12 months At 12 months
Year 2 to 4: every 3-6 months After 5 years: every 12 months
After 5 years: every 6 months
Monitor PSA kinetics
Table 3: The different surveillance strategies for patients on active surveillance.
Triggers for Active Treatment
While on active surveillance, nearly a third of patients will be re-
staged at high risk of disease progression and will be offered radical
treatment. The most common trigger for intervention is a change from
low-risk to intermediate or high-risk disease based on the Gleason
score, PSA level or stage [30]. The detection of Gleason pattern 4 or 5
on repeat biopsy will trigger a change from active surveillance to active
treatment, although some protocols will continue to keep patients with
Gleason 7 on AS if they decline treatment [23]. A PSA doubling time
of less than 2-4 years may also cause a shift to definitive therapy.
However, specific criteria for active treatment are not well defined [22].
Patient’s choice, largely due to anxiety of untreated cancer, can also
play a role [31].
Outcomes of Active Surveillance
Multiple studies have published their experience with active
surveillance. The largest prospective study on active surveillance is the
PRIAS study, which included 2499 patients [26]. The patients were
followed for a median of 1.6 years. PSA density and the number of
positive cores were found to be the strongest predictors for disease
progression. The disease-specific survival rate was 100% and the
authors concluded that AS was a feasible approach to reduce over-
treatment.
In a large study by Klotz et al. [32], which included 993 patients,
more than 200 patients were followed for ≥ 10 years and 50 for more
than 15 years. After a median follow-up of 6.4 years, 73% remained on
active surveillance. Disease-specific survival was 98.5%.
A study of 500 patients at the University of California in San
Francisco showed that 24% of men received treatment after a median
of 3 years on an active surveillance protocol [16]. 38% had an
upgrading of their Gleason score on repeat biopsy, which was the main
trigger for treatment.
A single-centre prospective cohort study from the Royal Marsden
Hospital included 471 patients with a median age of 66 years and a
median PSA of 6.4 ng/mL [33]. At a median follow-up of 5.7 years, the
5-year rate of adverse histology was 22% and the probability of not
receiving treatment during that time period was 70%. There were 2
prostate cancer-related deaths.
In another cohort of 407 patients, 59% remained on active
surveillance at a median follow-up of 3.4 years [34]. 25% underwent
curative treatment at a median of 2.2 years following diagnosis and
16% were either lost to follow-up, withdrew from AS or died of other
causes.
Soloway at al. [18] also published their data on 99 patients
undergoing active surveillance with a mean follow-up of 45 months
and a mean age of 66 years. 5 patients underwent radical treatment
with either surgery or radiotherapy and were recurrence-free for up to
83 months. No patients died of prostate cancer in that cohort. PSA
doubling time and clinical stage were found to be strong predictors of
disease progression.
All these studies suggest that active surveillance can be a suitable
alternative to immediate radical treatment provided that patients are
carefully selected with a strict surveillance protocol. However, AS is
based on the assumptions that the cancer is clinically insignificant and
that disease progression can be reliably identified and treated with
curative intent without affecting survival. These assumptions are
questionable and constitute some of the drawbacks of AS. Longer
follow-up data are needed to confirm the safety of this strategy.
Future of Active Surveillance
Active surveillance has proven to be a suitable alternative to
immediate radical treatment for men with low-risk localised prostate
cancer. However, the future of AS and its uptake will depend on
improved patient selection and timely identification of disease
progression [14]. We are now able to detect low-risk disease with
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greater accuracy. In the future, multi-parametric magnetic resonance
imaging (MRI) and novel biomarkers will play a major role in patient
selection and follow-up [35]. Improvements in prostate imaging as well
as the discovery of new serum markers will change the approach to the
management of patients with localised prostate cancer by enhancing
the current risk stratification systems. This will lead to better selection
of ideal candidates for active surveillance and better monitoring.
Active surveillance may therefore be offered earlier to more patients. It
is also likely that enhanced MRI techniques will reduce the number of
prostate re-biopsies. Promising biomarkers such as PCA3 and
TMPRSS2:ERG have already shown improved accuracy for predicting
biopsy outcomes. MicroRNAs (miRNAs), which as short non-coding
RNAs, have also been found to be potential biomarkers in prostate
cancer [36]. However, the studies investigating their use so far have
only involved small number of patients. Some of the miRNAs involved
in prostate cancer development include miR-20a, miR-21, miR-145
and miR-221 [37]. Implementing these markers can help reduce the
burden associated with AS monitoring, but further studies are needed
to validate their use [38].
Conclusion
Active surveillance for low-risk prostate cancer remains an
attractive option for men who want to avoid side-effects associated
with treatment. This approach enables them to retain the option of
radical treatment if there is evidence of disease progression during
follow-up. Active surveillance has been shown to be safe in the
medium term. Several published AS series have demonstrated that the
disease-specific mortality remains low. Careful selection of patients
however is key to a successful AS programme. The inclusion criteria
and follow-up protocols to identify disease progression have not yet
been standardised and various parameters are taken into account when
recruiting or monitoring patients. Risk stratification still remains a
significant challenge in active surveillance. The use of multi-parametric
MRI and novel biomarkers will certainly significantly change our
approach to AS when it comes to selecting patients and surveillance.
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